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534Efficacy and Safety of Ex Vivo Cultured Adult Human
Mesenchymal Stem Cells (Prochymal) in Pediatric
Patients with Severe Refractory Acute Graft-Versus-
Host Disease in a Compassionate Use Study
Vinod K. Prasad,1 Kenneth G. Lucas,2 Gary I. Kleiner,3 Julie An M. Talano,4
David Jacobsohn,5 Gloria Broadwater,6 Rod Monroy,7 Joanne Kurtzberg1Preliminary studies using directed-donor ex vivo expanded human mesenchymal stem cells (hMSCs) have
shown promise in the treatment of acute graft-versus-host disease (aGVHD). However, their production
is cumbersome and standardization is difficult. We describe the first experience of using a premanufactured,
universal donor, formulation of hMSCs (Prochymal) in children (n5 12; 10 boys; 9 Caucasian; age range: 0.4-
15 years) with treatment-resistant grade III and IV aGVHDwho received therapy on compassionate use basis
between July 2005 and June 2007 at 5 transplant centers. All patients had stage III or IV gut (GI) symptoms and
half had additional liver and/or skin involvement. Disease was refractory to steroids in all cases and addition-
ally to a median of 3 other immunosuppressive therapies. The hMSCs (8 106cells/kg/dose in 2 patients and
2 106cells/kg/dose in the rest) were infused intravenously over 1 hour twice aweek for 4 weeks. Partial and
mixed responders received subsequent weekly therapy for 4 weeks. HLA or other matching was not needed.
The hMSCs were started at a median of 98 days (range: 45-237) posttransplant. A total of 124 doses were
administered, with a median of 8 doses (range: 2-21) per patient. Overall, 7 (58%) patients had complete re-
sponse, 2 (17%) partial response, and 3 (25%) mixed response. Complete resolution of GI symptoms oc-
curred in 9 (75%) patients. Two patients relapsed after initial response and showed partial response to
retreatment. The cumulative incidence of survival at 100 days from the initiation of Prochymal therapy
was 58%. Five of 12 patients (42%) were still alive after a median follow-up of 611 days (range: 427-1111)
in surviving patients. No infusional or other identifiable acute toxicity was seen in any patient. Multiple infu-
sions of hMSCs were well tolerated and appeared to be safe in children. Clinical responses, particularly in the
GI system, were seen in the majority of children with severe refractory aGVHD. Given the favorable results
observed in a patient population with an otherwise grave prognosis, we conclude that hMSCs hold potential
for the treatment of aGVHD, and should be further studied in phase III trials in pediatric and adult patients.
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The treatment of severe (grades III-IV) acute
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significant benefits, and no therapy has been FDA ap-
proved for the treatment of aGVHD. In general, ap-
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ever, the response rates are lower and GVHD recur-
rence is higher in patients with grades III-IV disease
[1,2]. At present, many steroid-refractory patients die
from aGVHD and/or from complications arising
from the disease or its treatment [3]. The poor progno-
sis of severe aGVHD was well documented in a large
worldwide registry-based study of pediatric and adult
patients with probabilities of overall survival (OS) for
grade III and IV aGVHD to be close to 30% and
5%, respectively [4]. The 2-year survival was 10% or
lower in patients failing steroid therapy in another
study [5]. These poor outcomes underline the need
for novel therapeutic options for patients with
aGVHD in general and those with severe and refrac-
tory disease in particular.
The humanmesenchymal stem cells (hMSCs) arise
from themesoderm and have the ability to differentiate
into various tissues including bone, cartilage, andmus-
cle [6]. They have been shown to inhibit T cell activa-
tion, suppress inflammatory responses, and decrease
the secretion of immunosuppressive factors in labora-
tory studies [7-10]. In addition, these cells express
growth factors including vascular endothelial growth
factors (VEGF), which are known to aid angiogenesis
and tissue repair [11]. They also secrete various cyto-
kines including IL-6, IL-11, leukemia inhibitory factor
(LIF), stem cell factor, and macrophage colony-
stimulating factor [11-13]. Coculture experiments
have shown that hMSCs can induce a more anti-
inflammatory and tolerant state in dendritic cells, naı¨ve
and effector T cells, and natural killer (NK) cells by al-
tering cytokine secretion profiles [14]. These and other
studies have clearly demonstrated immunosuppressive
and tissue repair capabilities of hMSCs. For example,
suppression of allogeneic reaction and prolongation
of skin graft survival was seen in baboons following ad-
ministration of major histocompatibility complex
(MHC) mismatched MSCs [7]. These observations
point to another attractive aspect of hMSCs; that is,
the lack of HLA class II or costimulatory molecule ex-
pression of their cell surface rendering them
impervious to rejection by the recipient.
Given these biological properties, hMSCs have the
potential of being useful in the treatment ofGVHD. In
a 2004 report, ex vivo expanded haploidentical hMSCs
was first used to successfully treat a patient with grade
IV refractory aGVHD [15]. Subsequent human expe-
rience, albeit limited, with directed donor or universal
donor hMSCs in the treatment of aGVHD has been
encouraging [16,17]. Recently, a multicenter study
by Le Blanc et al. [18] demonstrated efficacy of
directed donor hMSCs in the treatment of adult and
pediatric patients with steroid refractory aGVHD. In
view of the poor prognosis of severe treatment-
refractory aGVHD and lack of a good and effective
treatment, we initially evaluated Prochymal, a com-mercial preparation of hMSCs derived from the bone
marrow (BM) of universal donors [19]. Here we de-
scribe the first experience of this compassionate use
study for the treatment of pediatric patients with re-
fractory grades III and IV aGVHD.PATIENTS AND METHODS
Study Design and Patient Eligibility
The compassionate use multicenter protocol was
designed to treat children (\18 years of age) with
severe steroid-refractory aGVHD and to evaluate the
safety and efficacy of hMSC infusion in these patients.
The patients were eligible if they had developed grade
III-IV aGVHD as defined by standard criteria after
HSCT transplant and were refractory to standard
first-line treatment with corticosteroids and at least 1
second-line therapy. They were considered steroid
refractory as defined by lack of response after at least
3 days of treatment with methylprednisone ($2 mg/
kg/day) or equivalent. Patients with uncontrolled
infection, irreversible organ failure, allergy to bovine
or porcine products, recipients of transplant for solid
tumors, and those with conditions that might interfere
with informed consent or evaluation were excluded.
Safety endpoints included infusional toxicity, adverse
reactions, development of ectopic tissue, infection,
and death. Efficacy endpoints included improvement
on the overall grade of aGVHD, response by organ
and OS. Patients were evaluated for safety until death,
withdrawal, or 180 days after the first infusion of
hMSC, whichever occurred first.
Between July 2005 and June 2007, a total of 12
children were enrolled at Duke University Medical
Center (n 5 5), Milton Hershey Medical Center
(n 5 3), University of Miami (n 5 2), Medical Col-
lege of Wisconsin (n 5 1), and Children’s Memorial
Hospital, Chicago (n 5 1). Detailed demographic
information is presented in Table 1. In summary,
the median age was 6 years (range: 5 months to 15
years); 10 were boys, and 9 were Caucasian. The pa-
tients had undergone HSCT for acute myelogenous
leukemia (n 5 4), acute lymphoblastic leukemia
(ALL) (n 5 2), familial hemophagocytic lymphohis-
tiocytosis (n 5 2), malignant osteopetrosis (n 5 1),
Hurler syndrome (n 5 1), adrenoleukodystrophy
(n 5 1), and myeloproliferative disorder with eosino-
philia (n51). Eleven patients had undergone myeloa-
blative conditioning (MAC), whereas 1 received
reduced-intensity conditioning (RIC). The graft
sources were unrelated umbilical cord blood (n 5
7), unrelated BM (n 5 2), unrelated peripheral blood
stem cell (n 5 1), cord blood (CB) plus CD341 cells
from a haploidentical-related parent (n 5 1), and CB
plus BM from a matched sibling (n 5 1). Three pa-
tients were on hemodialysis for acute renal
Table 1. Patient Demographic Information
Patient No.
Patient
Sex
Patient Age
(Years) Diagnosis
Conditioning
Regimen Graft
Donor
HLA Match
GvHD
Prophylaxis
1 Male 0.4 ALD MAC BM + UCB (sibling) 6/6 CsA
2 Male 0.7 M. OP RIC UCB 4/6 FK/MP
3 Male 6 HLH MAC BM 10/10 CsA/MTX
4 Male 2 Hurler MAC UCB 4/6 CsA/MMF
5 Male 13 AML MAC UCB 4/6 CsA/MMF
6 Male 2 AML MAC UCB 5/6 CsA/MMF
7 Male 15 HLH MAC UCB + haplo PBSC 5/6 CsA/MP
8 Male 4 ALL MAC PBSC 9/10 FK/MTX/ATG
9 Male 15 AML MAC UCB 5/6 CsA/MP
10 Female 2 MPD MAC UCB 6/6 CsA/MP
11 Female 6 AML MAC UCB 4/6 CsA/MMF
12 Male 13 ALL MAC BM 10/10 CsA/MTX
ALD indicates adrenoleukodystrophy; ALL, acute lymphocytic leukemia; AML, acute myelogenous leukemia; HLH, hemophagocytic lymphohistiocytosis;
Hurler, Hurler’s syndrome; M OP, malignant osteopetrosis; MPD, myeloproliferative disorder with eosinophilia; MAC, myeloablative conditioning; RIC,
reduced-intensity conditioning; BM, bone marrow; UCB, umbilical cord blood; PBSC, peripheral blood stem cells; haplo PBSC, CD34-selected PBSC
from haploidentical parent; CsA, cyclosporine A; FK, tacrolimus; MTX, methotrexate; MMF, mycophenolate mofetil, MP, methylprednisone.
536 Biol Blood Marrow Transplant 17:534-541, 2011V. K. Prasad et al.insufficiency at the time of hMSC therapy. The last
follow-up on the patients was in August to September
2008. Written informed consent according to the
declaration of Helsinki was obtained in all cases
from parent or legal guardian. All patients were ap-
proved by institutional review boards of participating
centers and by the FDA with parental signature by
FDA regulations (21 CFR Part 50), written authori-
zation for use and disclosure of personal health infor-
mation (45 CFR 164), and International Conference
on Harmonization guidelines, as applicable.hMSC Production
The hMSC were manufactured and provided by
Osiris Therapeutics, Inc. (Columbia, MD, USA). The
product lots of hMSC used in this study were derived
from the BM of 4 different donors aged 18 to 30 years,
who had been screened and tested according to FDA re-
quirements for Blood and Tissue Based Products, and
were manufactured under GMP guidelines by a scaled
adaptation of the technique described by Pittenger
et al. [6]. The cells were grown as symmetric fibroblastic
colonies, resulting in a homogeneous cell population
positive for surface antigens, CD105 (SH-2), CD 73
(SH-3, SH-4) CD29, CD44, CD71, CD90, CD106,
CD120a, CD124, and CD166 and negative for markers
of hematopoietic lineages CD14, CD34, and CD45.
The cells were formulated in PlasmaLyteA containing
5% human serum albumin (HSA) and 10% dimethyl
sulfoxide (DMSO) in a final volume of 15 mL and cryo-
preserved. The in-process intermediate and final lots
were tested for potential viral pathogens, mycoplasma,
sterility, endotoxin, cell identity, purity, and viability be-
fore being released for clinical distribution. The cells
were shipped frozen in a dry shipper to each site and
stored in the vapor phase of liquidnitrogen at each inves-
tigating transplant center.hMSC Infusion
On the day of administration, appropriate num-
bers of bags were thawed and 25 mL of PlasmaLy-
teA added to each bag. The reconstituted cellular
product was expected to have a viability of $70%
and the DMSO concentration of the infused product
was 3.75%. The hMSCs were administered intrave-
nously (i.v.) within 5 hours of thawing at a rate of 4
to 6 mL/min by infusion pump for patients weighing
$35 kg and over 60 minutes for those \35 kg.
Patients were premedicated with hydrocortisone and
diphenhydramine both at 0.5 to 1 mg/kg up to 50
mg i.v., given within 30 minutes prior to infusion.
Vital signs and oxygen saturation were monitored
for each infusion. Oxygen saturation (SaO2/SAT)
was monitored by pulse oximeter for at least 30
minutes prior to and until 2 hours after the start of
hMSC infusion. The infusion could be halted if there
was respiratory distress, a decrease in SaO2/SAT to
\85% for over 3 minutes, or if there was another
adverse event that the physician believed was related
to hMSC infusion.Therapy Schedule
Patients were scheduled to receive hMSC infusions
twice a week (administered at least 3 days apart) for 4
consecutive weeks. The first 2 patients received 8 
106 hMSCs/kg per infusion. The cell dose for the subse-
quent 10 patients was decreased to 2  106 hMSCs/kg
per dose after protocol amendment. A lower dose was
being used in a definitive adult study at that time [16].
At the conclusion of ‘‘induction therapy,’’ aGVHD
assessmentwas performedonday132 (62days) to eval-
uate for response. No additional infusions were admin-
istered to patients showing a complete response (CR)
or no response. However, patients continued to receive
weekly hMSC infusions as ‘‘maintenance therapy’’ at
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Biol Blood Marrow Transplant 17:534-541, 2011 537Ex Vivo Cultured Adult Human Mesenchymal Stem Cellsthe same cellular dose for an additional 4 weeks if day 32
assessment showed a partial or mixed response.
Assessment of aGVHD and Statistical Analyses
Baseline aGVHD prior to start of hMSC therapy
was graded according to standard criteria [20]. Using
the same criteria, aGVHD was graded on day 132
from the start of hMSC therapy and again after comple-
tion of therapy if the patient received maintenance dos-
ing. Responses were defined as follows: CR, resolution
of aGVHD in all evaluable involved organs; partial re-
sponse (PR), a decrease of at least 1 GVHD stage in
any 1 organ systemwithout aworsening in any other or-
gan system; mixed response (MR), a decrease of at least
1GVHD stage in any 1 organ systemwithworsening in
other organ system; no response (NR), no change in any
organ system or worsening in 1 or more organ system
without improvement in any other organ system. De-
tails of steroid and other concurrent immunosuppres-
sive therapy were recorded. hMSC therapy was
administered in combination with preexisting GVHD
therapies in accordancewith the individual institutional
guidelines. The primary response endpoint was as-
sessed at day132 from the start of hMSC therapy and
the responses were scored as CR, PR, MR, and NR as
defined earlier. Clinical status including any aGVHD
or chronic GVHD (cGVHD) was assessed at the most
recent follow-up in August to September 2008. OS in
the whole cohort and various response groups were cal-
culated using
Kaplan-Meier method. Safety and other efficacy mea-
sures are expressed using descriptive statistics.T
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s.RESULTS
Patient and aGVHD Characteristics
All enrolled patient (n 5 12) received hMSC
therapy. At the initiation of hMSC therapy, 7 patients
had grade IV and 5 had grade III aGVHD. Severe gas-
trointestinal involvement was seen in all patients with 7
patients showing stage 4 and 5 patients showing stage 3
symptoms. In addition to the gut, 2 patients had liver
and skin, 1 patient had liver, and 3 patients had skin
involvement. All 12 patients were steroid refractory
and in addition had failed 2 to 5 (median of 3) other
immunosuppressive therapies (Table 2). The patients
were a median of 98 days posttransplantation (range:
45-237) and the median duration between the diagno-
sis of aGVHD and initiation of hMSC therapy was 46
days (range: 18-157).
Prochymal Infusion
A total of 124 doses of hMSC were administered,
with a median of 8 infusions (range: 2-21) per patient
and detailed in Table 3. The median total cumulative
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538 Biol Blood Marrow Transplant 17:534-541, 2011V. K. Prasad et al.hMSC cell dose per patient was 21  106 cells/kg
(range: 6-108  106 cells/kg). Patient 2 received only
2 doses during the initial induction therapy. After
initial response, 2 patients (#2 and #3; Table 2) had
a flare-up of GVHD 2 and 4 weeks after the last infu-
sion and were treated again with hMSC after an
amendment to the original protocol was granted.
Safety
hMSC therapy was well tolerated, and no infu-
sional or other treatment-related toxicities were
observed. One patient (patient #4) with preexistent
respiratory distress related to the underlying diagnosis
and recent history of endotracheal intubation and sur-
gery was transferred to the intensive care unit within
24 hours of the second hMSC infusion. The event
was deemed not likely related to the hMSC infusion.
He received subsequent infusion per induction proto-
col and tolerated them well. During this period his
respiratory status improved while hMSC therapy was
continued. He eventually made complete respiratory
and aGVHD recovery and was discharged home.
Almost 2 years later, he remains well, is off all immuno-
suppressive therapy, and has normal total and fraction-
ated lymphocyte count and normal immunoglobulin
levels. In patient #2 (malignant osteopetrosis) calcified
ectopic lesions developed in the scalp and foot after
hMSC therapy. However, excision biopsies of these le-
sions revealed no evidence of DNA from the infused
hMSC, and thus the lesions were not considered to
be a result of hMSC therapy. These DNA analyses
were carried out at the Immunogenetics Testing
Laboratories (IMGL) of the University of Maryland
Medical Center (Baltimore, MD) and performed using
a multiplex short tandem repeat (STR) method. In ad-
dition, these lesions did not pose a serious health issue
and the patient remains alive to date. Three patients
were on dialysis prior to hMSC therapy. No patient
developed organ dysfunction related to MSCs while
on the study.
Response
At day 32 from the initiation of therapy, 2 patient
achieved CR, while 6 had PR and 3Mr. By completion
of therapy, 9 patients exhibited positive response to
hMSC therapy (Table 3). Seven patients (58%)
achieved CR, 2 (17%) PR, and 3 (25%) MR. Two pa-
tients (# 2 and #3) achieved CR after initial hMSC
therapy but later had a flare-up of GVHD, 1 with
grade IV skin and the other with grade IV gut. They
were retreated with hMSC, and both achieved partial
response and improved to grade I. All 12 patients
had severe gut involvement and responded to hMSC
to achieve a 75% (9/12) CR rate (Figure 1). The re-
maining 3 patients responded with a 1 to 2 stage im-
provement in their gut symptoms. Two of these
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Figure 1. Responses in various organs at the end of Prochymal therapy.
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from stage 0 to stage 1. All patients with skin GVHD
refractory to steroid therapy achieved resolution of
their skin disease after hMSC therapy. However, 2 pa-
tients (#5 and #11) who had no skin involvement at the
initiation of therapy subsequently developed stage 1
skin involvement. Of the 4 patients with liver involve-
ment 1 achieved CR, 1 had PR,whereas 2 patients in-
creased their stages (1 patient from stage 0 to I and 1
patient from stage III to IV).Figure 2. Kaplan-Meier estimates of the probability of 2-year OS according to
plete response to Prochymal, and whereas the remaining 5 patients (Non-CR)
a median of 611 days (range, 427-1111).Survival
The cumulative incidence of survival at day 32 and
day 100 from the initiation of hMSC therapy was
100% and 58%, respectively. Five of 12 patients
(42%) were still alive after a median follow-up for
surviving patients of 611 days (range: 427-1111). All
surviving patients had achieved CR following hMSC
therapy. The KM estimates of OS for patients achiev-
ing CR was 68% (95% CI 40%-100%) at 2 years. For
the whole group, the probability of OS at 2 years was
40% (95% confidence interval [CI] 20%-)0%)
(Figure 2). For the deceased (n 5 7), the median
time to death was 58 days (range: 36-185) from the ini-
tial hMSC infusion. The causes of death are listed in
Table 3. One patient who died 58 days after starting
hMSC had been withdrawn from the protocol at the
parents’ request after only 3 infusions. She had devel-
oped posterior reversible encephalopathy syndrome,
a complication that was most likely a result of her pre-
existent calcineurin-inhibitor therapy. Two of the CR
patients died of infectious complications (Xanthomonas
and Pseudomonas aeruginosa), which led to sepsis and
multiorgan failure. The causes of death in 5 patients
with PR or MR included respiratory failure from
multimicrobial pneumonia, renal failure, lymphopro-
liferative disorder, and cytomegalovirus (CMV)
encephalitis. One CR patient required a liver trans-
plantation on day 19 of hMSC induction therapy
for pretransplant hepatic insufficiency secondary to
the patient’s underlying disease (hemophagocyticGVHD response following Prochymal therapy. Seven patients had a com-
had partial or mixed response. Surviving patients have been followed for
540 Biol Blood Marrow Transplant 17:534-541, 2011V. K. Prasad et al.lymphohistiocytosis) that had progressed through the
HSCT. This patient continued to receive hMSC infu-
sions shortly after receiving his liver transplant. Unfor-
tunately, he died 85 days after the first hMSC infusion
because of respiratory failure resulting from a bacterial
infection. One patient (patient #4) in the CR group
and 1 (patient #11) in the MR group developed Fusa-
rium infection. The first patient was successfully
treated and is alive without evidence of GVHD for
25months. The second patient died of multisystem or-
gan failure while on therapy for the Fusarium infec-
tion. No hMSC therapy-related mortality was
observed.DISCUSSION
We report the first experience using Prochymal to
treat refractory aGVHD in children undergoing
allogeneic HSCT. Availability of hMSC as a premanu-
factured, quality-controlled product ready for use
without either HLA matching or lengthy on-site
manipulation makes it an attractive therapeutic option
for patients with severe aGVHD. hMSC was adminis-
tered at varying dosing schedules and for a length of 1
to 7 months. Responses were seen in all patients in 1 or
more organ systems. All 3 patients requiring dialysis
were able to receive hMSC therapy. Ectopic tissue
was seen in 1 patient but molecular studies showed it
to be composed of recipient and hematopoietic donor
DNA and not of the infused hMSC cells. In general,
Prochymal was well tolerated by the whole cohort
and no infusional or acute toxicity was observed during
124 infusions.
Despite small numbers, it is encouraging to see CR
in 58% of children with severe aGVHD that were re-
sistant to steroid and other immunosuppressive agents
in this compassionate study. In addition, CR increased
the probability of OS at 2 years to 68%. Importantly,
only 2 of 7 patients achieving CR died, whereas none
of the non-CR patients survived. The deaths were
either related to infection or multi organ system failure
both likely to be consequences of GVHD, immuno-
suppression, and from cumulative toxicity of all thera-
pies. It is noteworthy that serious infection was lower
in CR patients, and only 1 CR patient died of over-
whelming infection. It is difficult to assess causality
in heavily treated immunosupressed patients, but it is
likely that cumulative toxicity of preceding or
on-going therapies or active GVHD contributed to
the observed infections in nonresponders. Lower
infection in responders may reflect improved gut in-
tegrity following therapeutic response. All 12 patients
in this report were heavily pretreated. Significant
responses in this cohort may point to a better response
to hMSC therapy in pediatric patients, a finding
supported by Le Blanc et al.’s report of a betterresponse rate in children compared to adults (84% ver-
sus 60%) receiving directed donor hMSCs [18].
A high response rate (75%) in severe gut GVHD is
particularly noteworthy because they have historically
been more difficult to treat [2]. One may hypothesize
that the high CR rate in the GI disease may reflect
the combination of homing, broad immunomodula-
tory, and tissue repair properties of MSCs. Multiple
animal models of injury including cerebral ischemia,
radiation, and myocardial infarction have demon-
strated the homing property of MSC [21-24]. Other
studies have also demonstrated that MSCs can
preferentially improve clinical symptoms of lower GI
tract [18]. Tissue repair properties of hMSCs may
provide additional help in healing the mucosal break-
down, which is responsible for the severity of gut
symptoms. The patients achieving CR had a much
better OS and longer term outcome than those who
achieved a PR or MR. A long gap of 6 to 7 weeks
between the diagnosis of aGVHD and therapy with
hMSC and inclusion of only severe and resistant
patients in this study may be responsible for some of
the therapeutic failures and poor outcome in those
not achieving CR. All patients have been on other
immunosuppressive agents, and it is possible that
some of the responses seen after hMSC therapy may
reflect late responses to prior and concurrent thera-
pies. Only large controlled studies could resolve this
question. At present, many other questions about
hMSC’s remain unanswered. These include clinical
questions like the appropriate dosing and schedule of
administration and biological questions related to
their homing, longevity, half-life, and differences
related to the various donors.
Other studies have also demonstrated the poten-
tial usefulness of hMSCs as well as their tolerability
and safety. A recent study utilizing hMSCs derived
from family and other donors to treat severe
therapy-resistant aGVHD was published [18]. In
that study, of the 55 patients treated, 30 achieved
CR (55%) and 9 (16%) achieved PR. Similar to our
findings, CR patients had improved OS compared
to patients with less than CR (2-year posttransplant
survival, 53% versus 16%, P 5 .018). In an earlier
study, GVHD symptoms improved in 6 of 8 patients,
with complete resolution in the gut (n 5 6), liver (n 5
1), and skin (n 5 1) [17]. In a clinical trial of 32 adults
with grades II-IV aGVHD treated with a combination
of corticosteroids (2 mg/kg/day for at least 1 week)
and 2 doses of either 2  106 hMSCs/kg (n 5 17)
or 8  106 hMSCs/kg (n 5 15), 94% patients
achieved overall response and 77% achieved CR by
28 days [16]. There was no response difference
between the 2 dosing arms in that study.
Current therapy for severe aGVHD refractory to
steroids is limited and ineffective in a large proportion
of patients. In addition, a proportion of steroid
Biol Blood Marrow Transplant 17:534-541, 2011 541Ex Vivo Cultured Adult Human Mesenchymal Stem Cellsresponsive patients will develop steroid dependence
and suffer frommultiple toxicities associated with pro-
longed systemic steroid therapy. hMSC does not
appear to have overlapping toxicities with the conven-
tional immunosuppressive agents used to treat patients
with refractory aGVHD. Importantly, histocompati-
bility matching between the patient and the MSCs is
not required for either efficacy or safety because
MSCs do not express either HLA class II or accessory
molecules like CD40, CD80, and CD86 [9]. Given en-
couraging results from this limited study, hMSC
should be further studied to assess its usefulness in
the treatment of patients with GVHD.
In conclusion, hMSC therapy appears to be a safe
and potentially effective treatment option for pediatric
patients with aGVHD who have failed steroids and
other immunosuppressive therapies. The lack of
overlapping toxicities with conventional immunosup-
pressive medications allows it to be a considered as
an additional agent for patients with steroid refractory
aGvHD. A larger multicenter, prospective, random-
ized placebo-controlled Phase III trial evaluating
hMSC infusion for treatment of steroid-refractory
aGVHD in both pediatric and adult patients was
recently completed.ACKNOWLEDGMENTS
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